Oncoinvent

Kalender

	Est. tid*
2025-08-27	20:20	Kvartalsrapport 2025-Q2
2025-08-04	N/A	Extra Bolagsstämma 2025
2025-05-15	-	X-dag ordinarie utdelning ONCIN 0.00 NOK
2025-05-14	-	Årsstämma
2025-04-28	-	Bokslutskommuniké 2024

Beskrivning

Land	Norge
Lista	Euronext Growth Oslo
Sektor	Hälsovård
Industri	Bioteknik

Oncoinvent är ett radiofarmaceutiskt bolag i klinisk fas som utvecklar behandlingar för solida cancerformer. Teknikplattformen är fokuserad på användningen av alfa-emitterande radionuklider för att leverera strålning direkt till cancerceller. Bolagets produktkandidat, Radspherin®, är en alfa-strålterapikandidat designad för lokal behandling av cancer som har spridit sig till kroppshåligheter. Oncoinvent har sitt huvudkontor i Oslo.

Filter

År

Typ

Språk

Rensa

2025-07-03 15:45:00 Oncoinvent ASA: Notice of Extraordinary General Meeting 1,71 NOK | -9,81% | 0,04 MNOK

2025-06-30 22:11:30 Oncoinvent AS: Announcement of fully underwritten rights issue 1,80 NOK | -2,70% | 0,75 MNOK

2025-06-30 22:01:27 Oncoinvent AS: BerGenBio and Oncoinvent, a rising innovator in radiopharmaceutical cancer therapies, announce proposed merger and a fully underwritten rights issue 1,80 NOK | -2,70% | 0,75 MNOK

2025-06-18 08:01:55 Oncoinvent (ONCIN): Invitation to Presentation of Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases 1,99 NOK | +2,68% | 4,30 MNOK

2025-06-18 07:00:00 ONCIN: Oncoinvent Announces Positive Final Data from Phase 1/2a Trial of Radspherin® in Patients with Colorectal Peritoneal Metastases 1,99 NOK | +2,68% | 4,30 MNOK

2025-05-14 14:39:38 ONCIN: Minutes from the annual general meeting 2025 1,70 NOK | -5,23% | 0,29 MNOK

2025-04-30 13:41:52 ONCIN: Notice of Annual General Meeting 2,75 NOK | -3,17% | 0,79 MNOK

2025-04-28 20:22:37 Oncoinvent ASA: Annual Report 2024 2,84 NOK | +1,43% | 1,47 MNOK

2025-04-28 08:05:00 Oncoinvent ASA: Invitation to Presentation of Q1 2025 company update 2,80 NOK | +64,71% | 1,86 MNOK

2025-04-28 08:00:00 Oncoinvent Reports updated 18-Month Data from Phase 1 Ovarian Cancer Trial with Radspherin®: No new recurrences Demonstrate Continued Promise of Preventing Disease Progression 2,80 NOK | +64,71% | 1,86 MNOK

2025-04-28 07:45:49 ONCIN: Financial calendar 2,80 NOK | +64,71% | 1,86 MNOK

2025-03-25 07:00:00 ONCIN: Oncoinvent ASA Announces Positive Safety Review of Lead-In Cohort, Advances to Randomised Part of Ongoing Phase 2 Trial of Radspherin® in Ovarian Cancer Patients 2,00 NOK | -4,76% | 0,70 MNOK

2025-03-05 10:57:39 Oncoinvent ASA: Mandatory notification of trade 1,60 NOK | +6,67% | 0,24 MNOK

2025-02-27 07:30:00 Oncoinvent ASA: Fourth Quarter 2024 Update and Results 1,71 NOK | -11,67% | 0,72 MNOK

2025-02-27 06:54:46 ONCIN: Oncoinvent ASA reports completed inclusion in the initial safety lead-in cohort of the phase 2 trial of Radspherin® in Ovarian Cancer Patients 1,71 NOK | -11,67% | 0,72 MNOK

2025-02-20 07:42:23 Oncoinvent ASA: Invitation to Result Presentation Q4 2024 2,00 NOK | -1,72% | 0,56 MNOK

2025-02-19 07:45:00 ONCIN: Oncoinvent ASA to present at various conferences 2,04 NOK | -5,35% | 0,84 MNOK

2025-02-18 09:47:46 Oncoinvent ASA: Registration of new share capital 2,15 NOK | -2,27% | 0,75 MNOK

2025-02-06 20:09:41 Oncoinvent ASA: Final results of the subsequent offering and allocation of offer shares 2,50 NOK | -8,76% | 0,41 MNOK

2025-02-06 08:00:00 Oncoinvent ASA: Last day of the subscription period in the subsequent offering 2,74 NOK | +3,40% | 0,07 MNOK

2025-02-04 14:38:01 Oncoinvent ASA: Grant of share options - mandatory notification of trade 2,50 NOK | -1,19% | 0,22 MNOK

2025-01-23 08:00:00 Oncoinvent ASA: Commencement of subscription period for subsequent offering 2,72 NOK | -2,86% | 0,18 MNOK

2025-01-22 12:55:41 Oncoinvent ASA: Key information relating to subsequent offering 2,80 NOK | -3,11% | 0,10 MNOK

2025-01-22 12:46:01 Oncoinvent ASA: Resolution to increase the share capital in connection with subsequent offering 2,80 NOK | -3,11% | 0,10 MNOK

2024-12-18 08:04:15 ONCIN: Financial calendar 3,00 NOK | 0,00% | 0,33 MNOK

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Oncoinvent

Kalender

Beskrivning

Språk

Typ

År

Språk

Typ

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden